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Abstract
Background: Use of hyaluronic acid-based products has become a valuable alternative to drug-based approaches
in the treatment of recurrent aphthous stomatitis (RAS). The presented study aimed to investigate the effect of a
barrier forming hyaluronic acid containing mouth wash or a topical gel formulation on the healing of RAS and
patient’s quality of life.
Methods: For this single-center retrospective study, medical records of the Dental School of the University of Brescia
were screened for adult and systemically health patients suffering from minor recurrent aphthous stomatitis (RAS) and
treated with either a barrier forming, hyaluronic acid containing mouth wash (GUM® AftaClear® rinse) or a topical gel
(GUM® AftaClear® gel) in 2015. All patients fulfilling the in−/exclusion criteria and presenting full data sets on lesion
diameter, lesion color, as well as pain perception for baseline (day 0) and 4 and 7 days after treatment were enrolled
into the presented study.
Results: Out of 60 screened patients, a total of 20 patients treated with the Rinse formulation and 25 treated with the
Gel formulation were eligible for the enrollment into this study. Both groups showed equal distribution in patient’s age,
sex and presented a similar mean lesion size (3.0 ± 1.0mm), lesion color distribution as well as pain perception at baseline.
All patients showed significant normalization of lesion color, reduction of pain, and lesion dimension within the course of
their treatment. After 7 days, the mean percentage of lesion reduction was highly significant for both groups attaining
77.4 ± 30.1% in the Rinse group and 81.2 ± 23.1% in the Gel group with a complete lesion closure obtained in 60 and
56% of the cases, respectively. However, a significant (p < 0.05) higher percentage of lesions in the Gel group (72%)
compared to the Rinse group (40%) showed an improvement in lesion size already after 3 days.
Conclusions: Within the limitation of retrospective design, it can be concluded that both the barrier forming hyaluronic
acid containing mouth rinse as well as the topical gel formulation are effective in the treatment of minor recurrent
aphthous stomatitis (RAS), with a trend for an earlier healing onset for the topical Gel formulation.
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Background
Mouth ulcers represent a very common unpleasant oral
mucosal disease that can reduce patient’s quality of life,
due to the presence of a painful stinging sensation that
worsen during daily activities like speaking, eating or even
drinking [1]. Causes include physical trauma, radiation,
chemical injury, and microbial infection (bacterial, viral,
and fungal). However, some ulcerations, such as recurrent
aphthous stomatitis (RAS), commonly known as aphthae
or canker sores, have uncertain etiology and causes of
RAS are not fully elucidated [1]. Nevertheless, they share
a similar etiopathology. Commonly observed histopatho-
logical changes in the pre-ulcerative stage include infiltra-
tion of the epithelium by mononuclear (lymphocytic)
cells before an edema, followed by keratinocyte
vacuolization and focal vasculitis causing localized
swelling. This tumefaction ulcerates and infiltration of
neutrophils, lymphocytes, and plasma cells occurs
until healing and epithelium regeneration. The pro-
gression accompanied by a cell-mediated immune
response involves T-cells and promotes tumor necrosis fac-
tor alpha (TNF-α) generation by activated macrophages [2].
Although the histopathological progression of the
aphthous lesions formation follows a common pat-
tern, triggers vary between individuals and may in-
clude nutritional deficiencies, local trauma, stress,
hormonal influences, allergies, genetic predisposition
or other factors [3]. Most RAS appear on non-
keratinizing oral mucosa, which excludes the attached
gingiva, the hard palate and the dorsum of the
tongue. Still there are less common, more severe
forms that may also involve keratinizing epithelial
surfaces. Symptoms associated with RAS can range
from a minor nuisance, local stinging that can inter-
fere with eating and drinking, whereas, the severe
forms may be debilitating, even causing weight loss
due to malnutrition [3].
RAS can be classified phenotypically into 3 different
types although their classification vary slightly in
terms of size and healing time between different au-
thors [3–6]: 1. Minor RAS are the most frequently
observed (80%) small, round, clearly defined below
commonly below 5mm in diameter (2–3mm in average)
but painful ulcers that typically heal between 7 and
14 days without scaring. 2. Major RAS that account
for about 10% of all RAS are larger (diameter exceeds
10 mm) and deep, can last for 6 weeks or longer, and
are affecting both mucosa and keratinized tissues, and
frequently heal with scaring. 3. Herpetiform RAS,
may look ‘herpetic’ in nature but do not have a viral
etiology, are mostly present as multiple small clusters
of pinpoint lesions that form large irregular ulcers,
and similar to minor RAS, heal within 14 days with-
out scaring.
Therefore, the majority of the RAS will heal within
10–14 days without any complication, and ulceration
episodes occur 3–6 times per year [3–5].
Incidence of RAS in the general population is esti-
mated around 25%, with an early onset during adoles-
cence or even childhood [4, 5]. The most frequently
employed treatments for RAS are anti-inflammatories,
corticosteroids, analgesics and antimicrobial, but also lu-
bricating and healing promoting agents are used [5].
Even more advanced anti-TNF-α treatments have been
developed using therapeutic molecules directly targeting
TNF-α production and, by that, reducing inflammation
an immunological host response. However, such ap-
proaches suffer from severe side effects ranging from
somnolence to nausea and gastrointestinal symptoms.
By consequence, Thalidomide, being the most effective
and reliable agent among them, is still limited to short
term use considering its side effects. Since RAS con-
ditions can last for several years with reoccurring epi-
sodes of ulceration before gradually disappearing,
long-term exposure to this medication seems not to
be appropriate. [5, 7–10].
To overcome the limitations of short term application
and severe side effects, other therapeutics have been in-
vestigated for the treatment of RAS, including the use of
Vitamine B12 [11], silver nitrate [12] and plant extracts
[13, 14] with limited success.
In order to get away from a drug-based treatment ap-
proach, topically applied mucosal protectants have been
developed aiming to form a temporal physical barrier
over the ulcerous lesion protecting it from oral traumas
[15]. Such an oral wound patch preventing the detri-
mental and often painful contact with the milieu of oral
cavity and food and beverage components, therefore,
reducing pain and fostering the healing process [16]. To
maintain the barrier in place, the domiciliary application
must be repeated several times during day until reso-
lution of the ulcer. Initial clinical studies using topical
gels containing hyaluronic acid have shown promising
results, demonstrating a significant reduction of the
healing time as well as a relief of pain reached by
using physical barriers without any reported side-
effects [15–18].
Within this class of treatments, two new topical prod-
ucts containing hyaluronic acid as well as mucoadhesive
components have recently been introduced in the mar-
ket: a gel formulation that can be applied directly on the
ulcer (GUM® AftaClear® gel, Etoy, Switzerland) and
mouth rinse formulation forming a thin layer in situ
after rinsing (GUM® AftaClear® rinse, Etoy, Switzerland).
Even if hyaluronic acid efficacy in RAS treatment is well
known in the literature, it is also reported that patient
compliance and topical agent retention on the oral mu-
cosa play a key role in clinical effectiveness. Hyaluronic
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acid retention is mediated and influenced by formulation
of preparation used to convey this agent on the ulcers
area, and therefore it varies not only between different
products, but also between different administrations
ways, such as topical gel, spray or mouth rinse of the
same product. Moreover, patient’s compliance is influenced
by single formulation characteristics, such as the easiness of
use or the pleasant of both product taste and texture. For all
the above mentioned reasons it is always prudent, before a
priori accepting the beneficial effects of a new product, to
clinically test it.
Therefore to evaluate the performance and safety of
these two recently available formulations, a retrospective
study has been designed aimed to the collection of clin-
ical data from RAS patients treated at the University of
Brescia in Italy during the period of January 1st to
December 31st in 2015.
Methods
Patient selection
This single-center observational retrospective study was
approved from the Ethical Committee of Spedali Civili
of Brescia (NP 2544) on 20-12-2016. Data was obtained
from files of adult patients suffering from recurrent
aphthous stomatitis (RAS) arrived to Dental School of
the University of Brescia and recruited for a prospective
study that, for organizational reasons, was interrupted
before its completion.
Briefly, patients using the GUM® AftaClear® mouth
rinse formulation rinsed for 60 s for 3 times per day,
after meals, repeating as necessary. Patients using the gel
formulation applied around 1 cm of the oral gel for to
each ulcer for 3 times per day, after meals, repeating as
necessary, while used a medium-bristled manual tooth-
brush during healing period.
Inclusion criteria were: male and female patients aged
18–60 years, treated during the year 2015 at the Dental
School of the University of Brescia; use of GUM® Afta-
Clear® gel or GUM® AftaClear® rinse for aphthous mouth
ulcers for at least 7 days; report of recurrent aphthous
ulceration onset during the last 6 months before start of
aphthous mouth ulcer treatment; and registration into
the clinical file from baseline till the end of treatment of
an evaluation in terms of ulcer dimension and redness
of the lesions at different times, e.g. on first day, after 3
days of treatment and/or after 7 days of treatment. Red-
ness of ulcerous lesions was assessed as follows: stage 6
- intense grey-yellow with red edges (GY-R); stage 5 - in-
tense grey-yellow without red edges (GY); stage 4 - yel-
low (Y); stage 3 - grey (G); stage 2 - red (R); and stage 1
- normalized (N).
Exclusion criteria were: history of any treatment for
cancer in the last 3 months; recurrence of cancer and
end stage of it; presence of severe systemic diseases,
auto-immune or virus-based oral mucosal diseases; lac-
tation or pregnancy; use of any medication to treat ul-
cers the previous week before gel or rinse use started or
use of local medication or systemic drug during the
treatment with gel or rinse.
Data collection
No specific sample size was calculated for data collec-
tion. All patients have been included that started the
treatment with either rinse or topical gel formulation in
the period from January to December 2015, that met the
inclusion/exclusion criteria, and sufficient data could be
retrieved from their medical records.
After the inclusion/exclusion criteria assessment, the
following information were independently collected by
two investigators and compared for exactness:
1. Patient demographics (age, gender).
2. Type of recurrent aphthous stomatitis (RAS):
Minor ≥4 mm and < 10 mm, Minor < 4 mm,
herpetiform. Major aphthous lesions were excluded.
3. Initial size of each ulcer or, in herpetiform cases, of
the biggest one.
4. Type of formulation used for the treatment (Rinse
or Gel).
5. Frequency of application per day.
6. Decrease of the lesion dimension after 3 and 7 days
(in %).
7. Change of color of the ulcerous lesions was
characterized using a six stages scale: stage 6 - intense
grey-yellow with red edges (GY-R); stage 5 - intense
grey-yellow without red edges (GY); stage 4 - yellow
(Y); stage 3 - grey (G); stage 2 - red (R); and
stage 1 - normalized (N).
8. Reported Pain intensity on 4 levels (No = 0, low = 1,
medium = 2, high = 3) at the treatment beginning,
after 3 and 7 days.
9. Number of patients with disturbance while eating
and drinking.
10. Number of patients with reported improvement in
quality of life.
11. Adverse events and adverse device events and
concomitant medication.
Data were recorded in a web-based electronic case re-
port form (CeRF) by the Investigators, after the medical
chart check was carried out for each patient. Each inves-
tigator entered data via a secure network, with access re-
quiring specific username and password. Data management
and statistical evaluation was carried out by a fully
blinded external CRO ensuring confidentiality and
compliance with applicable data privacy protection
laws and regulations.
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Statistical analysis
Standard descriptive statistics were performed. Means ± SD
was calculated for all parameters. To determine the statis-
tical significance (#p < 0.001; *p < 0.05) of changes within
groups a non-parametric Wilcoxon signed rank test was
used since normal distribution of the difference could not
be guaranteed. Still, a parametric paired sample t-test was
used to calculate p-values within groups.
To test for statistical significant difference between
the groups at different time points, a non-parametric
Wilcoxon rank sum test was used to calculate p-values.
p < 0.05 was considered to be significant.
The “N-1” Chi-squared test (https://www.medcalc.org/
calc/comparison_of_proportions.php) as recommended
by Campbell [19] was used to assess significant difference
between proportions of percentage of closure between the
two groups.
Results
Patient population
Out of 60 screened subjects, 45 fulfilled the in/−exclusion
criteria and were enrolled into the study. Twenty were
treated with rinse and 25 were treated with gel. Twenty-one
of the patients were females (Rinse = 11; in the Gel = 10)
and 24 were males (9 in the Rinse and 15 in the Gel group).
All of them were aged between 24 and 59 years. Mean age
of patients treated with the rinse formulation (Rinse) was
45 ± 10 years and 43 ± 12 years for the patients treated with
the gel formulation (Gel). The different types of recurrent
aphthous stomatitis (RAS) (Minor ≥4mm and < 10mm,
Minor < 4mm, herpetiform) were equally distributed be-
tween the two groups (Fig. 1), with 35% Minor ≥4mm and
< 10mm (7), 50% Minor < 4mm (10), and 15% herpetiform
(3) in the Rinse group; and 32% Minor ≥4mm and < 10mm
(7), 56% Minor < 4mm (10), and 12% herpetiform (3) in the
Gel group. Average lesion size at baseline was equivalent for
both groups and all lesions had a grey yellow appearance
before the beginning of treatment (Figs. 2 and 3).
Since the baseline, all patients reported pain of dif-
ferent intensity and difficulties in eating and/or drinking.
Most patients did apply the rinse as recommended in the
instructions for use, 3 times a day. In detail, the rinse was
administered 3 times/day by 18 (90%) patients and 5 times/
day by 2 (10%) patients; the gel was administered 3 times/
day by 22 (88%) patients and 5 times/day by 3 (12%)
patients. Neither adverse events (AE) nor concomitant
medications were reported in patient’s files during the 7-
day treatment, assuring on the lack of interferences with
the healing process, or any of study assessments such as
pain perception.
Reduction of mean aphthous lesion diameter and
percentage of lesion closure
Both groups presented a similar distribution of RAS
types and identical mean lesion diameter of 3.0 ± 1.0 mm
(Fig. 2; Table 1) at baseline.
Fig. 1 Distribution of recurrent aphthous stomatitis (RAS) types
at baseline
Fig. 2 Mean aphthous lesion diameter [mm] and mean percentage
of lesion closure [%]
Fig. 3 Overall distribution of percentage of lesion closure after 3
and 7 days (all sites)
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All sites showed a significant improvement of lesion
dimension during the observed treatment period. Over-
all percentage of mean lesion closure in 45 patients was
significantly increased over the observed period averaging
to 25.6% ± 28.4% at day 3 and 79.5% ± 26.2% at day 7,
respectively. In total, 3 patients (7%) showed a complete
closure of the lesion after 3 days and 26 (58%) presented a
complete healing after 7 days (Table 2).
Looking at the individual treatment groups separately,
the percentage of mean lesion closure was significant
(17.9 ± 26.8%, p = 0.0442) for the Rinse group and highly
significant (31.7 ± 28.7, p = 0.0000000365) for the Gel
group after 3 days (Table 1). After 7 days, the mean
percentage of lesion closure was highly significant for
both groups compared to baseline, attaining 77.4 ±
30.1% in the Rinse group and 81.2 ± 23.1% in the Gel
group (Table 1). In principle, no statistically significant
differences (p < 0.05) could be observed between the two
treatment groups regarding the mean percentage of le-
sion closure or the number of completely healed sites
(100% healing – Fig. 4) at any observation time-point.
Although, neither the overall mean percentage of le-
sion closure nor the percentage of sites with complete
lesion closures did reveal significant differences between
the two groups. Regarding the percentage of sites
showed healing progression, a significant difference
could be observed. At day 3, 40% of all RAS treated with
the Rinse formulation did show a reduction of their le-
sion diameter (> 0% healing), whereas already 72% of all
lesion treated with the Gel formulation showed improve-
ments from baseline compared with the same period
(Table 2; Fig. 4). This difference was statistically signifi-
cant (p < 0.0327). After 7 days, a certain delay in healing
in the Rinse group compared to the Gel group was still
evident when looking at the percentage of RAS with per-
centage of lesion closure of less than 50% (Fig. 4–0%
and > 0- < 50%). Still 20% of the RAS in the Rinse
group, but only 4% in the Gel group, showed a per-
centage of lesion closure inferior to 50% after 7 days.
However, this difference did not reach statistical sig-
nificance (p = 0.0933) after 7 days.
Overall, neither the age nor the gender of the patient,
nor the type or baseline size of RAS had a significant in-
fluence on the lesion healing progression in this study.
Appearance of aphthous lesions at baseline, 3 days, and
7 days (color)
Coloration of the aphthous lesions can give additional in-
formation about the healing progression. The appearance
of the aphthous lesions were graded from intense grey-
yellow with red edges (GY-R) to faded without red edges
(GY), Red color (R), Yellow (Y), Grey (G), and normal ap-
pearance (N). Reduction of redness and adaptation of le-
sion color to surrounding mucosa was judged as a sign for
healing. At baseline, all lesions displayed an intense grey-
yellow color, whereas, 40% in the Rinse group and 56% in
the Gel group displayed additional red edges. This indi-
cated that all lesions represented fresh, unhealed aphthous
ulcers (Fig. 5). There was no statistical difference between
the two groups in terms of appearance at baseline.
Healing progression, assessed by reduction of lesion
redness, and change in coloration towards a more
normal appearance were noticed in all patients, with
first positive results already visible after 3 days of
treatment. Forty-two subjects (93.30%) out of all
treated 45 patients (Rinse and Gel) showed already a
Table 1 Mean lesion diameter and percentage of lesion closure after 3 and 7 days
n Lesion diameter [mm] Percentage of closure [%]
baseline 3 days 7 days baseline 3 days 7 days
All 45 3.0 ± 1.0 2.3 ± 1.2 0.8 ± 1.0 0 25.6 ± 28.4 79.5 ± 26.2
p-value – 1.17E-8# 5.94-E24# – – –
Rinse 20 3.0 ± 1.0 2.5 ± 1.2 0.9 ± 1.2 0 17.9 ± 26.8 77.4 ± 30.1
p-value – 0.0442# 3.29E-10# – – –
Gel 25 3.0 ± 1.1 2.2 ± 1.2 0.7 ± 0.9 0 31.7 ± 28.7 81.2 ± 23.1
p-value – 3.65E-07# 8.88E-15# – – –
#p < 0.001; *p < 0.05 for Wilcoxon Signed Rank Test; p-value from paired sample t-test
Table 2 Distribution of lesion closure grade within the two treatment groups after 3 and 7 days
Grade of
closure
3 days 7 days
All (n = 45) Rinse (n = 20) Gel (n = 25) All (n = 45) Rinse (n = 20) Gel (n = 25)
100% 7% 5% 8% 58% 60% 56%
50- < 100% 18% 10% 24% 31% 20% 40%
> 0- < 50% 33% 25% 40% 11% 20% 4%
0 42% 60% 28% 0% 0% 0%
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color improvement of lesion at day 3. In both groups,
lesion color changed from intense grey-yellow appearance
with red edges (GY-R) or faded grey-yellow appearance
without red edges (GY) to grey (G), yellow (Y), red
(R) or normalized (N) appearance after 3 days. Only 3
patients already presented a normal lesion color after
3 days, however lesions appearance was judged normal
in a total of 25 patients (55.55%) after 7 days. Changes of
coloration over time were statistically significant (p < 0.05)
for both treatment groups. However, no statistical dif-
ferences in the composition of lesion colors was ob-
served between the two groups at any time-point.
Improvement of quality of life, changes in pain intensity,
and disturbance when eating or drinking
All except 1 patient (Gel group) stated their quality of life
has improved during the treatment with the Rinse and the
Gel formulation until day 7. The diameter of baseline le-
sion of respective patient was rather large (diameter of 4
mm) and it was only reduced to 50% from its initial size
until the end of treatment, where a lesion diameter of 2
mm was still detectable. Although he did not report on
any disturbance while eating or drinking and at day 7 he
still score his pain as medium level. Unfortunately, no fur-
ther data was available to better explain his subjective
assessment.
At baseline, all 45 patients reported pain and stinging sen-
sation with different intensity, furthermore issues with either
drinking or eating or both were highlighted. Mean percep-
tion of pain intensity (none = 0, low = 1, medium= 2,
high = 3) in the two groups was similar at baseline (Rinse =
1.90 ± 0.72; Gel = 1.92 ± 0.81) and significantly decreased at
day 3 (Rinse = 1.10 ± 0.85; Gel = 1.16 ± 0.85) and day 7
(Rinse =0.45 ± 0.76; Gel = 0.40 ± 0.65), respectively (Table 3).
There were no statistically significant differences in
terms of reported mean pain intensity (p < 0.05) between
the two groups at any time-point.
A total of 5 patients (35%) in the Rinse group and 6
patients (24%) in the Gel Group reported no pain after
3 days, whereas 12 patients (70%) in the Rinse group and
17 patients (68%) in the Gel group were free of pain
after 7 days (Fig. 6).
Independently from their pain intensity, all patients
(100%) in the Rinse group reported a disturbance
when eating and 50% when drinking at baseline (Fig. 7).
Likewise, patients with problems in eating represented
96% and those with problems in drinking represented
60% of patients in the Gel group at baseline. Both
these disturbances while eating and drinking did not
improve significantly at day 3, irrespective of the
treatment (Fig. 7). However, the reduction of patients
reporting a disturbance when eating or drinking was
highly significant for both groups after 7 days
compared to baseline as well as the 3-day time point
(p < 0.0001). No significant difference between the two
treatment groups could be observed at any of the time-
points (Table 4).
After 7 days only 7% of the patients still reported some
disturbance when eating, whereas, only 2% still felt pain
when drinking (Fig. 6).
Fig. 4 Degree of lesion closure for Rinse and Gel group after 3 and 7 days
Table 3 Mean reported pain intensity at baseline and after 3
days and 7 days
Mean pain score (± SD)
Baseline 3 days 7 days
Rinse 1.90 ± 0.72 1.10 ± 0.85 0.45 ± 0.76
p-value – 4.6E-08# 9.8E-11#
Gel 1.92 ± 0.81 1.16 ± 0.85 0.40 ± 0.65
p-value – 1.7E-07# 2.5E-12#
#p < 0.001,*p < 0.05 for Wilcoxon Signed Rank Test; p-value from paired
sample t-test
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Discussion
The recurrent aphthous stomatitis (RAS) is the most
common form of recurrent oral ulcers. RAS is charac-
terized by recurring painful lesions in the mouth with
a round or ovoid appearance and inflammatory halos.
Individual aphthous ulcers may be morphologically
classified in 3 different types. Minor RAS are shallow
lesions in mucosa with diameters up to 5 mm and
heal over 7 to 14 days. Major RAS exceed 10 mm, are
deep, can affect also the keratinized mucosa, and heal
over several weeks, sometimes with scaring. The her-
petiform RAS are commonly 2–3 mm in diameter,
however patterns fusing into bigger ulcers and varying
in diameter and depth as well in the healing time, gener-
ally reported between 10 and 14 days, are described [1, 5,
16]. In order to investigate the performance of a barrier
forming, hyaluronic acid-based gel and mouth rinse for-
mulation in the treatment of active RAS, through the as-
sessment of lesion and pain reduction, only patients
with minor RAS and herpetiform types with a lesion
diameter between 2 and 5 mm were considered for
this retrospective study.
Results reported in this study corroborate the trend
towards a faster or earlier healing of the lesions treated
with the topical Gel is expected, even if both groups dis-
played a very similar mean lesion reduction after 7 days.
In this study patients could choose freely between
the Rinse or Gel formulation, based on their individual
preference irrespective of their initial situation. Both for-
mulations showed to be very effective and indicated in
treatment of minor and herpetiform RAS in general. The
presented clinical data seem to indicate a preference to-
wards the topically applied Gel in the most acute phase of
ulceration (first 3 days) and in larger ulcer diameters.
Moreover, the Rinse formulation seems to be the ideal ap-
plication form to prevent formation of RAS before an
aphthous lesion is visible, due to its ability to reach the en-
tire oral cavity. A daily application could, therefore, reduce
the frequency of recurrence of RAS. However, the effect
on the recurrence frequency was not investigated in this
Fig. 5 Distribution of lesion color grades at baseline and after 3 and 7 days
Fig. 6 Distribution of reported pain intensity at baseline and after 3 and 7 days
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study and it would need to be investigated in prospective
design.
Regarding methodological aspects, limitation of the
presented retrospective study is lack of a negative con-
trol, placebo or sham group. Moreover prospective ran-
domized controlled trial based on these results might be
useful in order to test effects of these treatments on a
negative control, placebo, or sham group. Nevertheless,
feasibility to compare this database of signs and symp-
toms to those in up-to-date literature might be a great
opportunity both to consolidate existing knowledge and
to address future clinical studies in inclusion and exclu-
sion criteria designing. RAS is a quite widespread patho-
logical condition in population, so that clinicians and
general dental practitioners could take advantage from
this study also to manage the anamnestic information
of their patients and to collect a proper and workable
medical file.
Still, sufficient publications reporting on the treatment
of RAS with similar or drug-based approaches and pre-
senting data on equivalent clinical endpoints (percentage
of lesion reduction and pain perception) exist and allow
a comparison to our data.
Both, results here obtained on percentage of lesion
closure as well as on percentage of completely healed
site at day 3 and 7 were comparable or superior to data
reported from other groups using similar topically
applied barrier-forming protective agents in minor RAS
types of around 3mm diameter. For example, application
of a film-forming triamcinolone acetonide (TA) pomade
or a triester glycerol oxide gel (TGO) resulted in a 38 and
46% of mean lesion reduction after 4 days, and 70 and
77% after 7 days, respectively [20]. Although the results
from the 3 days’ time points in our study cannot be com-
pared to the 4 days’ time point in their study, after 7 days,
percentage of lesion closure was found to be equal or in-
ferior to our results. Similar findings were reported in a
study including 16 patients with minor RAS of around 3
mm diameter treated with a topical application of a 0.2%
hyaluronic acid gel (Gengigel®) [16]. Although the group
assessed healing after 14 days only, the maximum ulcer
size was found to be reduced by 62%, number of ulcers
per patient was reduced only by 50% during this elongated
period. Moreover, 18.8% of the patients still reported to
feel no improvement after 14 days.
Solely data from a study investigating the topical appli-
cation of anti-inflammatory and anti-bacterial drugs
showed slightly superior results in terms of mean lesion
reduction with 75 and 54% of reduction after 4 days and
95 and 80% reduction after 7 days, for a 2% quercetin
loaded hydroxyethylcellulose gel and its control a benzy-
lamine hydrochloride-based mouth rinse, respectively.
Although no patients in the quercetin group reported
any side effects, 8 patients applying the benzylamine
hydrochloride complained of a stinging sensation after
rinsing. Considering the low risk profile of a drug-free for-
mulation compared to the risks associated with the daily
application of an anti-bacterial and anti-inflammatory drug,
Table 4 Distribution of reported pain intensity within the two treatment groups (Rinse, Gel)
Baseline 3 days 7 days
Rinse (n = 20) Gel (n = 25) Rinse (n = 20) Gel (n = 25) Rinse (n = 20) Gel (n = 25)
High 4 (20%) 7 (28%) 1 (5%) 4 (20%) 0 (0%) 0 (0%)
Medium 10 (50%) 9 (36%) 5 (25%) 8 (32%) 4 (15%) 2 (8%)
Low 8 (30%) 9 (36%) 9 (45%) 10 (40%) 4 (15%) 6 (24%)
None 0 (0%) 0 (0%) 5 (25%) 6 (24%) 12 (70%) 17 (68%)
Fig. 7 Percentage of patients with eating and drinking disturbance at baseline and after 3 and 7 days
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the slightly faster healing reported, probably also related to
a slightly different measurement and study population,
seems not to outweigh the possible risks.
Our results showed percentage of complete lesion
closure equivalent and even superior to the results re-
ported for treatment with 2% Quercetin or benzylamine
hydrochloride. Only 60% of the lesion in the quercetin
gel group and only 35% in the benzylamide hydrochloride
group reached full closure after 7 days. [21]
In our study assessment of lesion color changes during
the treatment supported an early improvement of the
aphthous lesions (Fig. 7), moreover relationship between
reported pain and changes of diameter and lesion color
was clearly detected.
Some comparison with following reported clinical data
can be drawn, even if in our study a 4-level pain scale
(none, low, medium, high) instead of a Visual Analog
Scale (VAS) was used to assess pain. Ofluoglu and co-
workers [18, 20] reported that after topical application
of a pomade formulation, a reduction to a normal pain
level (healed = > 95% VAS reduction) was achieved in
only 1.9% in the TA group, 8.9% in the TGO group, and
2% in the placebo after 6 days of treatment. The study
investigated another hyaluronic acid based topical for-
mulation (Gengigel®) reported a VAS score reduction by
65% after 14 days [16]. Furthermore, a total of 18.8%
patients reported no improvement of their situation after
14 days, which was likely related to their pain assessment.
Similar findings were reported for another hyaluronic acid
gel formulation test showing continues pain reduction
from day 0 to day 4 and 7 compared to a pomade
formulation [18]. In our study only 2% of all treated
patients reported to suffer from disturbances while drinking
after 7 days.
Conclusions
Within the limitation of the retrospective design of
the present study and based on the comparison to
the published literature, it can be concluded that both
these two barrier-forming hyaluronic acid based
mouth rinse (Rinse) and topical gel formulation (Gel)
are effective in the treatment of minor and herpeti-
form recurrent aphthous stomatitis (RAS), with a
trend for faster healing onset when the topical Gel
formulation is applied. Further prospective random-
ized clinical studies are necessary to assess the reduc-
tion of healing time compared to a control group and
to investigate the effect of the Rinse formulation on
the frequency of recurrence of RAS.
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